Clinical pharmacokinetics of fexofenadine enantiomers Miura & Uno Fexofenadine enantiomers PK

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 1, 2010, Pages 69-74

  Miura, Masatomo ^a   Uno, Tsukasa ^b  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Difference; Drug interaction; Enantiomer; Fexofenadine; Fexofenadine enantiomers; Mechanism; P glycoprotein; P glycoprotein mediated drug interaction; Pharmacokinetics

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; RIFAMPICIN; VERAPAMIL;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSPORT; ENANTIOMER; FOOD DRUG INTERACTION; FRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; SINGLE DRUG DOSE; SMALL INTESTINE ABSORPTION; STEREOCHEMISTRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSPORT KINETICS;

ANTIFUNGAL AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; ITRACONAZOLE; STEREOISOMERISM; TERFENADINE; VERAPAMIL;

EID: 72949098038     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903382615     Document Type: Review

References (42)

1. Simpson K, Jarvis B. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-321
2. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-871
3. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001;69:114-121
4. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738
5. Putnam WS, Ramanathan S, Pan L, et al. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 2002;91:2622-2635
6. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir. J Clin Pharmacol 2002;42:1269-1274
7. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003;33:1-5
8. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-463
9. Miura M, Uno T, Tateishi T, Suzuki T. Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal 2007;43:741-745
10. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19:223-227
11. Lemma GL, Wang Z, Hamman MA, et al. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006;79:218-230
12. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;7:17-23
13. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: A new model for drug interactions. Eur J Clin Invest 2003;33:10-16
14. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005;77:170-177
15. Dresser G.K, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50
16. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420
17. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005;78:191-201
18. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006;61:538-544
19. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000;293:376-382
20. Tsuruo T, Iida H, Naganuma K, et al. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 1983;43:808-813
21. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983;43:2267-2272
22. Belpomme D, Gauthier S, Pujade-Lauraine E, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000;11:1471-1476
23. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006;62:372-376
24. Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 2006;34:1875-1879
25. Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008;65:693-700
26. Sakugawa T, Miura M, P Hokama N, et al. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 2009;67:535-540
27. Ahlin G, Karlsson J, Pedersen JM, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008;51:5932-5942
28. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-370
29. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-414
30. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-168
31. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.Curr Drug Metab 2008;9:310-322
32. Howe R, Shanks RG. Optical isomers of propranolol. Nature 1966;210:1336-1338
33. Blaschke G, Kraft HP, Fickentscher K, Kohler F. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers Arzneimittelforschung 1979;29:1640-1642
34. Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996;52:1-12
35. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J Pharm Sci 1989;78:695-715
36. Walle T. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates. Drug Metab Dispos 1985;13:279-282
37. Kanazawa H, Okada A, Higaki M, et al. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J Pharm Biomed Anal 2003;30:1817-1824
38. Tybring G, Bottiger Y, Widen J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997;62:129-137
39. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:411-426 (Pubitemid 32656078)
40. Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 2006;126:395-402 (Pubitemid 44651288)
41. Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 2005;60:61-68 (Pubitemid 40942782)
42. Miura M, Tada H, Yasui-Furukori N, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5- hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 2004;60:623-628